Innovative all-in-one exome sequencing strategy for diagnostic genetic testing in male infertility: Validation and 10-month experience.
asthenozoospermia
azoospermia
diagnostics
gene panel
genetic testing
genetics
male infertility
oligozoospermia
teratozoospermia
Journal
Andrology
ISSN: 2047-2927
Titre abrégé: Andrology
Pays: England
ID NLM: 101585129
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
revised:
16
07
2024
received:
12
04
2024
accepted:
10
08
2024
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
24
8
2024
Statut:
aheadofprint
Résumé
Current guidelines indicate that patients with extreme oligozoospermia or azoospermia should be tested for chromosomal imbalances, azoospermia factor (AZF) deletions and/or CFTR variants. For other sperm abnormalities, no genetic diagnostics are recommended. To determine whether exome sequencing (ES) with combined copy number variant (CNV) and single nucleotide variant (SNV) analysis is a reliable first-tier method to replace current methods (validation study), and to evaluate the diagnostic yield after 10 months of implementation (evaluation study). In the validation study, ES was performed on DNA of patients already diagnosed with AZF deletions (n = 17), (non-)mosaic sex chromosomal aneuploidies or structural chromosomal anomalies (n = 37), CFTR variants (n = 26), or variants in known infertility genes (n = 4), and 90 controls. The data were analyzed using our standard diagnostic pipeline, with a bioinformatic filter for 130 male infertility genes. In the evaluation study, results of 292 clinical exomes were included. All previously reported variants in the validation cohort, including clinically relevant Y-chromosomal microdeletions, were correctly identified and reliably detected. In the evaluation study, we identified one or more clinically relevant genetic anomalies in 67 of 292 of all cases (22.9%): these included aberrations that could have been detected with current methods in 30 of 67 patients (10.2% of total), (possible) (mono)genetic causes in the male infertility gene panel in 28 of 67 patients (9.6%), and carriership of cystic fibrosis in nine of 67 patients (3.1%). ES is a reliable first-tier method to detect the most common genetic causes of male infertility and, as additional genetic causes can be detected, in our evaluation cohort the diagnostic yield almost doubled (10.2%-19.8%, excluding CF carriers). A genetic diagnosis provides answers on the cause of infertility and helps the professionals in the counseling for treatment, possible co-morbidities and risk for offspring and/or family members. Karyotyping will still remain necessary for detecting balanced translocations or low-grade chromosomal mosaicism.
Sections du résumé
BACKGROUND
BACKGROUND
Current guidelines indicate that patients with extreme oligozoospermia or azoospermia should be tested for chromosomal imbalances, azoospermia factor (AZF) deletions and/or CFTR variants. For other sperm abnormalities, no genetic diagnostics are recommended.
OBJECTIVES
OBJECTIVE
To determine whether exome sequencing (ES) with combined copy number variant (CNV) and single nucleotide variant (SNV) analysis is a reliable first-tier method to replace current methods (validation study), and to evaluate the diagnostic yield after 10 months of implementation (evaluation study).
MATERIALS AND METHODS
METHODS
In the validation study, ES was performed on DNA of patients already diagnosed with AZF deletions (n = 17), (non-)mosaic sex chromosomal aneuploidies or structural chromosomal anomalies (n = 37), CFTR variants (n = 26), or variants in known infertility genes (n = 4), and 90 controls. The data were analyzed using our standard diagnostic pipeline, with a bioinformatic filter for 130 male infertility genes. In the evaluation study, results of 292 clinical exomes were included.
RESULTS
RESULTS
All previously reported variants in the validation cohort, including clinically relevant Y-chromosomal microdeletions, were correctly identified and reliably detected. In the evaluation study, we identified one or more clinically relevant genetic anomalies in 67 of 292 of all cases (22.9%): these included aberrations that could have been detected with current methods in 30 of 67 patients (10.2% of total), (possible) (mono)genetic causes in the male infertility gene panel in 28 of 67 patients (9.6%), and carriership of cystic fibrosis in nine of 67 patients (3.1%).
CONCLUSION
CONCLUSIONS
ES is a reliable first-tier method to detect the most common genetic causes of male infertility and, as additional genetic causes can be detected, in our evaluation cohort the diagnostic yield almost doubled (10.2%-19.8%, excluding CF carriers). A genetic diagnosis provides answers on the cause of infertility and helps the professionals in the counseling for treatment, possible co-morbidities and risk for offspring and/or family members. Karyotyping will still remain necessary for detecting balanced translocations or low-grade chromosomal mosaicism.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Andrology published by John Wiley & Sons Ltd on behalf of American Society of Andrology and European Academy of Andrology.
Références
Punab M, Poolamets O, Paju P, et al. Causes of male infertility: a 9‐year prospective monocentre study on 1737 patients with reduced total sperm counts. Hum Reprod. 2017;32(1):18‐31. doi:10.1093/humrep/dew284
Olesen IA, Andersson AM, Aksglaede L, et al. Clinical, genetic, biochemical, and testicular biopsy findings among 1,213 men evaluated for infertility. Fertil Steril. 2017;107(1):74‐82.e7. doi:10.1016/j.fertnstert.2016.09.015
Tüttelmann F, Ruckert C, Röpke A. Disorders of spermatogenesis: perspectives for novel genetic diagnostics after 20 years of unchanged routine. Med Genet. 2018;30(1):12‐20. doi:10.1007/s11825‐018‐0181‐7
Nsota Mbango JF, Coutton C, Arnoult C, Ray PF, Touré A. Genetic causes of male infertility: snapshot on morphological abnormalities of the sperm flagellum. Basic Clin Androl. 2019;29:2. doi:10.1186/s12610‐019‐0083‐9
Minhas S, Bettocchi C, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 update on male infertility. Eur Urol. 2021;80(5):603‐620. doi:10.1016/j.eururo.2021.08.014
NVOG NVvOeG. Richtlijn Mannelijke subfertiliteit. (Version 1). 2010.
Houston BJ, Riera‐Escamilla A, Wyrwoll MJ, et al. A systematic review of the validated monogenic causes of human male infertility: 2020 update and a discussion of emerging gene‐disease relationships. Hum Reprod Update. 2021;28(1):15‐29. doi:10.1093/humupd/dmab030
Nagirnaja L, Lopes AM, Charng WL, et al. Diverse monogenic subforms of human spermatogenic failure. Nat Commun. 2022;13(1):7953. doi:10.1038/s41467‐022‐35661‐z
Wyrwoll MJ, Köckerling N, Vockel M, et al. Genetic architecture of azoospermia‐time to advance the standard of care. Eur Urol. 2023;83(5):452‐462. doi:10.1016/j.eururo.2022.05.011
Quarantani G, Sorgente A, Alfano M, et al. Whole exome data prioritization unveils the hidden weight of Mendelian causes of male infertility. A report from the first Italian cohort. PLoS One. 2023;18(8):e0288336. doi:10.1371/journal.pone.0288336
Ghieh F, Barbotin AL, Swierkowski‐Blanchard N, et al. Whole‐exome sequencing in patients with maturation arrest: a potential additional diagnostic tool for prevention of recurrent negative testicular sperm extraction outcomes. Hum Reprod. 2022;37(6):1334‐1350. doi:10.1093/humrep/deac057
Tang D, Li K, Geng H, et al. Identification of deleterious variants in patients with male infertility due to idiopathic non‐obstructive azoospermia. Reprod Biol Endocrinol. 2022;20(1):63. doi:10.1186/s12958‐022‐00936‐z
Kherraf ZE, Cazin C, Bouker A, et al. Whole‐exome sequencing improves the diagnosis and care of men with non‐obstructive azoospermia. Am J Hum Genet. 2022;109(3):508‐517. doi:10.1016/j.ajhg.2022.01.011
World Health Organization. WHO laboratory manual for the examination and processing of human semen. World Health Organization; 2021.
Mattocks CJ, Morris MA, Matthijs G, et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet. 2010;18(12):1276‐1288. doi:10.1038/ejhg.2010.101
Yaldiz B, Kucuk E, Hampstead J, et al. Twist exome capture allows for lower average sequence coverage in clinical exome sequencing. Hum Genomics. 2023;17(1):39. doi:10.1186/s40246‐023‐00485‐5
Krumm N, Sudmant PH, Ko A, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012;22(8):1525‐1532. doi:10.1101/gr.138115.112
Plagnol V, Curtis J, Epstein M, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics. 2012;28(21):2747‐2754. doi:10.1093/bioinformatics/bts526
Robinson JT, Thorvaldsdóttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24‐26. doi:10.1038/nbt.1754
Wallis YL, Payne SJ, Mcanulty C, et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. ACGS; 2013.
Smits RM, Oud MS, Vissers L, et al. Improved detection of CFTR variants by targeted next‐generation sequencing in male infertility: a case series. Reprod Biomed Online. 2019;39(6):963‐968. doi:10.1016/j.rbmo.2019.08.005
Dequeker E, Stuhrmann M, Morris MA, et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR‐related disorders–updated European recommendations. Eur J Hum Genet. 2009;17(1):51‐65. doi:10.1038/ejhg.2008.136
Vogt PH. AZF deletions and Y chromosomal haplogroups: history and update based on sequence. Hum Reprod Update. 2005;11(4):319‐336. doi:10.1093/humupd/dmi017
Krausz C, Navarro‐Costa P, Wilke M, Tüttelmann F. EAA/EMQN best practice guidelines for molecular diagnosis of Y‐chromosomal microdeletions: state of the art 2023. Andrology. 2024;12(3):487‐504. doi:10.1111/andr.13514
Zhang Y, Malekpour M, Al‐Madani N, et al. Sensorineural deafness and male infertility: a contiguous gene deletion syndrome. J Med Genet. 2007;44(4):233‐240. doi:10.1136/jmg.2006.045765
Krausz C, Hoefsloot L, Simoni M, Tüttelmann F. EAA/EMQN best practice guidelines for molecular diagnosis of Y‐chromosomal microdeletions: state‐of‐the‐art 2013. Andrology. 2014;2(1):5‐19. doi:10.1111/j.2047‐2927.2013.00173.x
Silber SJ, Repping S. Transmission of male infertility to future generations: lessons from the Y chromosome. Hum Reprod Update. 2002;8(3):217‐229. doi:10.1093/humupd/8.3.217
Noordam MJ, Repping S. The human Y chromosome: a masculine chromosome. Curr Opin Genet Dev. 2006;16(3):225‐232. doi:10.1016/j.gde.2006.04.018
Tyler‐Smith C, Krausz C. The will‐o'‐the‐wisp of genetics–hunting for the azoospermia factor gene. N Engl J Med. 2009;360(9):925‐927. doi:10.1056/NEJMe0900301
Dicke AK, Pilatz A, Wyrwoll MJ, et al. DDX3Y is likely the key spermatogenic factor in the AZFa region that contributes to human non‐obstructive azoospermia. Commun Biol. 2023;6(1):350. doi:10.1038/s42003‐023‐04714‐4
VKGL VKGL. Richtlijnen constitutionele cytogenetica V06. VKGL; 2020.
De Gregori M, Ciccone R, Magini P, et al. Cryptic deletions are a common finding in “balanced” reciprocal and complex chromosome rearrangements: a study of 59 patients. J Med Genet. 2007;44(12):750‐762. doi:10.1136/jmg.2007.052787
Tabet AC, Verloes A, Pilorge M, et al. Complex nature of apparently balanced chromosomal rearrangements in patients with autism spectrum disorder. Mol Autism. 2015;6:19. doi:10.1186/s13229‐015‐0015‐2
van der Sanden B, Schobers G, Corominas Galbany J, et al. The performance of genome sequencing as a first‐tier test for neurodevelopmental disorders. Eur J Hum Genet. 2023;31(1):81‐88. doi:10.1038/s41431‐022‐01185‐9
Schobers G, Derks R, den Ouden A, et al. Genome sequencing as a generic diagnostic strategy for rare disease. Genome Med. 2024;16(1):32. doi:10.1186/s13073‐024‐01301‐y
K.A.W. DNA Sequencing Costs: Data From the NHGRI Genome Sequencing Program (GSP). K.A.W.; 2024.
Kimmins S, Anderson RA, Barratt CLR, et al. Frequency, morbidity and equity—the case for increased research on male fertility. Nat Rev Urol. 2024;21(2):102‐124. doi:10.1038/s41585‐023‐00820‐4
Meng L, Liu Q, Tan C, et al. Novel homozygous variants in TTC12 cause male infertility with asthenoteratozoospermia owing to dynein arm complex and mitochondrial sheath defects in flagella. Front Cell Dev Biol. 2023;11:1184331. doi:10.3389/fcell.2023.1184331
Tucker EJ, Bell KM, Robevska G, et al. Meiotic genes in premature ovarian insufficiency: variants in HROB and REC8 as likely genetic causes. Eur J Hum Genet. 2022;30(2):219‐228. doi:10.1038/s41431‐021‐00977‐9
Goldberg Y, Halpern N, Hubert A, et al. Mutated MCM9 is associated with predisposition to hereditary mixed polyposis and colorectal cancer in addition to primary ovarian failure. Cancer Genet. 2015;208(12):621‐624. doi:10.1016/j.cancergen.2015.10.001
Soares de Lima Y, Arnau‐Collell C, Díaz‐Gay M, et al. Germline and somatic whole‐exome sequencing identifies new candidate genes involved in familial predisposition to serrated polyposis syndrome. Cancers (Basel). 2021;13(4):929. doi:10.3390/cancers13040929
Esteves SC, Roque M, Bedoschi G, Haahr T, Humaidan P. Intracytoplasmic sperm injection for male infertility and consequences for offspring. Nat Rev Urol. 2018;15(9):535‐562. doi:10.1038/s41585‐018‐0051‐8